<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03267589</url>
  </required_header>
  <id_info>
    <org_study_id>ENGOT-OV30 / NSGO</org_study_id>
    <nct_id>NCT03267589</nct_id>
  </id_info>
  <brief_title>Trial in Patients With Relapsed Ovarian Cancer</brief_title>
  <official_title>NSGO-OV-UMB1; ENGOT-OV30 / NSGO: A Phase II Umbrella Trial in Patients With Relapsed Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Society for Gynaecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GCIG: Gynecologic Cancer InterGroup</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Network of Gynaecological Oncological Trial Groups (ENGOT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SGCTG: The Scottish Gynaecological Cancer Trials Group, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PMHC: The Princess Margaret Hospital Consortium, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BGOG: Belgian Gynaelogical Onology Group, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KGOG: Korean Gynaelogical Onology Group, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GOTIC: Gynecologic Oncology Trial and Investigation Consortium, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NOGGO: Nord-Ostdeutsche Gesellschaft Fur Gynäkologische Onkologie, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>COGI: Cooperative Ovarian Cancer Group for Immunotherapy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ANZGOG: The Australia New Zealand Gynaecological Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nordic Society for Gynaecologic Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objectiv is to obtain preliminary evidence of efficacy of novel agents for the
      management of relapsed ovarian cancer, and in part 2 efficacy of novel agents compared to the
      standard of care (SoC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 16, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1: single cohorts of novel agents Part 2: randomized phase 2 against standard of care.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Disease control rate (DCR) (CR+PR+SD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) by RECIST v1.1</measure>
    <time_frame>10 months</time_frame>
    <description>PFS by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS by Immune-RECIST</measure>
    <time_frame>10 months</time_frame>
    <description>PFS by Immune-RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>Overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>10 months</time_frame>
    <description>Objective response rate according to RECIST v1.1 (ORR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of (Overall) Response (DoR)</measure>
    <time_frame>10 months</time_frame>
    <description>Duration of (Overall) Response (DoR)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: MEDI9447 (CD73) + durvalumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: MEDI0562 (OX40) + durvalumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: MEDI0562 (OX40) + tremelimumab combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562</intervention_name>
    <description>Three different combination are being tested. Each cohort has different combination</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Platinum-sensitive disease: defined as disease progression ≥ 6 months following the
             last administered dose of platinum-based therapy. Patients must have received atleast
             one line of chemotherapy for platinum-sensitive disease. OR

          2. Platinum-resistant disease: defined as disease progression &lt; 6 months following the
             last administered dose of platinum-based therapy.

             OR

          3. Platinum-refractory disease: defined as lack of response or disease progression while
             receiving the most recent therapy.

             Other key inclusion criteria:

          4. Histological confirmed ovarian, fallopian tube or peritoneal cancers.

          5. Histological types: high-grade serious, high-grade endometriod, undifferentiated,
             carcinosarcoma or mixed histology.

          6. Subjects must have at least 1 measurable lesion as defined by RECIST guidelines. This
             should not be the same lesion used for biopsy.

          7. Patients entering cohort A: Archival tumour tissue must be screened for CD73 and only
             CD73 positive patients (defined as &gt;10% of tumor cells positive) will enter this
             trial.

          8. Patient agrees to undergo all analysis (blood, serum, tissue); radiological
             examinations according to protocol.

          9. Mandatory tumour biopsy before treatment (before day 0) and at day 56 of treatment.

         10. Patients must give informed consent.

         11. Patients must be at least 18 years of age.

         12. ECOG performance status 0-1

         13. Serum albumin &gt;30g/l.

         14. Adequate organ function

         15. Life expectancy of at least 12 weeks.

         16. Patients must be fit to receive Investigational medical products (IMPs)

        Exclusion Criteria:

          1. Subjects using immunosuppressive medications within 14 days.

          2. Immunodeficiency or organ transplant

          3. Live vaccines within 28 days prior to the first dose.

          4. Major surgery within 28 days prior to the first dose.

          5. Ovarian sarcomas, small cell carcinoma with neuroendocrine differentiation,
             non-epithelial can-cers.

          6. Cancer therapies (chemotherapy, radiotherapy, surgery, immunotherapy, biologic or
             hormonal therapy) within 28 days prior to the first dose.

          7. Concurrent treatment with an investigational agent or participation in another
             clinical trial.

          8. Previous malignant disease: patients are not eligible for the study if actively being
             treated of inva-sive cancer other than ovarian cancer. Patients with previous
             malignant disease other than ovarian cancer who are relapse-free and treatment-free
             for more than three years may enter this study. Pa-tients with previous history of
             in-situ carcinoma, stage 1A cervical cancer or non-invasive basal cell and squamous
             cell skin carcinoma can enter this trial.

          9. Active infection including tuberculosis

         10. History of a cerebral vascular accident, transient ischemic attack or subarachnoid
             hemorrhage within the past 6 months.

         11. History of clinically significant hemorrhage in the past 3 months.

         12. Untreated CNS disease, leptomeningeal disease or cord compression. Subjects with
             treated dis-ease should have at least 4 weeks of neurologic and radiographic stability
             and be off steroids for 14 days.

         13. Significant cardiovascular disease's.

         14. Persistance of clinically relevant therapy related toxicity from previous anticancer
             therapy (any grade 3-4 toxicity or grade ≥2 neuropathy).

         15. Known hypersensitivity to the trial drugs, or to their excipients.

         16. Has had prior exposure to IMPs, or any other immunotherapy.

         17. Active or prior documented autoimmune or inflammatory disorders

         18. For cohorts B and C: Medical condition requiring current systemic anticoagulation, or
             a history of congenital hypercoagulable condition. Subjects taking aspirin at doses &lt;
             325 mg per day are eli-gible provided that prothrombin time is within the
             institutional range of normal. Use of local anti-coagulation for port maintenance is
             permitted
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mansoor R Mirza, MD</last_name>
    <phone>+4535459624</phone>
    <email>mansoor@rh.regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dorte Nørvang, RN</last_name>
    <phone>+4535453311</phone>
    <email>dorte.noervang@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VejleSygehus</name>
      <address>
        <city>Vejle</city>
        <state>Region Syddanmark</state>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jon Henriksen, MD</last_name>
      <email>Jon.Henriksen@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Jon Henriksen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>København Ø</city>
        <state>Sjaelland</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MANSOOR RAZA MIRZA</last_name>
      <phone>+4535459624</phone>
      <email>mansoor@rh.regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annika Auranen, MD</last_name>
      <email>anaura@utu.fi</email>
    </contact>
    <investigator>
      <last_name>Johanna Maenpaa, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <state>Haukeland</state>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Line Bjørge, MD</last_name>
      <email>Line.Bjorge@uib.no</email>
    </contact>
    <investigator>
      <last_name>Line Bjørge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristina Lindemann, MD, PhD</last_name>
      <phone>+47 22934000</phone>
      <phone_ext>5690</phone_ext>
      <email>klinde@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Kristina Lindemann, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2017</study_first_submitted>
  <study_first_submitted_qc>August 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>durvalumab</keyword>
  <keyword>tremelilumab</keyword>
  <keyword>MEDI 9447</keyword>
  <keyword>MEDI 0562</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

